38
Companies Industry News
Sorin to manufac- ture components for TAVI valve Sorin has announced that, after signing a supply agreement with Boston Scientific, it will manu- facture components of the Lotus transcatheter aortic valve implantation (TAVI) device at its site in Vancouver, Canada. A press release reported that under the terms of the supply agreement, Sorin Group will perform certain manufacturing steps related to the tissue valve of the Lotus.
Michel Darnaud,
president of Sorin Group, Cardiac Surgery Business Unit, said: “This agree- ment recognises the strong valve manufacturing ex- perience that Sorin Group has accumulated across its European and North American operations, building on more than 40 years of innovation, devel- opment, clinical validation and commercialisation in
the field of mechanical and tissue prosthetic heart valves.”
The Lotus is an investi- gational device worldwide, limited by applicable law to investigational use and not available for sale.
Maquet buys LAAx and its Ti- gerPaw system II occlusion device Maquet has announced it has acquired the company LAAx and its TigerPaw system II occlusion device. It has said that the TigerPaw system II will expand expand its cardiac surgery offering and will be launched in the USA and in Europe in June 2013. A press release reported that when implanted, the TigerPaw II safely and effectively occludes the left atrial appendage (LAA) and conforms to its shape and thickness, minimising the risk of tissue damage
and accidental bleeding associated with other common closing methods used during open chest procedures. The prod- uct has been cleared by regulatory bodies in the USA and EU and will be commercially available in those regions this month and in June 2013, respectively. TigerPaw II is an implantable LAA occlu- sion device featuring an exceptionally soft silicone fastener that conforms to the appendage anatomy and tissue thickness, spreading the pressure equally. According to the press release, it is the only device currently available that has been proven 100% occlusive of the LAA during cardiac surgery, due to the pliable silicone. “We believe TigerPaw II will be a best-in-class device for reliable ligation of the LAA, potentially mitigating post-operative
TigerPaw
stroke and its associated costs in patients with atrial fibrillation undergo- ing cardiac surgery,” said Peter Hinchliffe, president and chief executive officer for the Cardiac Surgery Business Unit of Maquet Cardiovascular.
Middle Peak Med- ical raises $8.5M for novel mitral valve technology Middle Peak Medical has announced that it has raised US$8.5M in a Series A financing. The proceeds will provide capital for further devel- opment of Middle Peak’s technology for treating mitral valve disease. According to a
company press release,
W
www.eacts.org/annual- meeting.aspx
Calendar of events
31 August–4 September ESC 2013 Amsterdam, The Netherlands W
www.escardio.org/con- gresses/esc-2013
15–17 September PCR London Values
W
www.pcrlondonvalves.com
12–15 September WSCTA - World Society of Cardio-Thoracic Surgeons Split, Croatia W
www.spektar-putovanja.hr/ WSCTS2012
4 October Top 10 in Cardiology Lausanne, Switzerland W
www.toptencardiology.com
5–9 October EACTS Vienna, Australia
27 October–1 November TCT 25
The Moscone Center, San Francisco, USA W
www.tctconference.com/
7–8 November RHC Asia Pacific Resistant Hypertension Course Singapore
following the financ- ing, Middle Peak will establish some of its clinical and regulatory operations in Europe. The company’s research and development centre will remain in Palo Alto. Michael Lesh, chief executive officer and co- founder of the company, commented: “Our inter- nal financing allowed us to show strong proof-of- concept of the Middle Peak mitral implant. We now have the resources to accelerate pre-clinical and clinical development. Middle Peak intends to bring significant benefit to patients with mitral regurgitation, the most common valvular heart disease.”
W
www.resistanthypertension- coursc...
1-3 December ICI—Innovations in Cardiovascular Interventions (1–3 Dec 2013) Tel-Aviv, Israel: W
icimeeting.com
12–13 December Gulf PCR Dubai, UAE W
www.gulfpcr.com
August 2013
Cardiovascular News team
Editor-in-chief: Dr Kevin Fox
Publisher: Stephen Greenhalgh
Head of Publishing: Marcio Brito Editor:
Dawn Powell
dawn@bibamedical.com
Editorial contribution: Frances Carson Angela Gonzalez
Design:
David Reekie Layout:
Matt Hadfield
Advertising: Sanna Eronen
sanna@bibamedical.com
Subscriptions: Sue Couch
subscriptions@bibamedical.com
Please contact the Cardiovascular News team with news or advertising queries Tel: +44 (0)20 7736 8788
Published by: BIBA Medical, 44 Burlington Road, Fulham, London, SW6 4NX, UK Tel: +44 (0) 20 7736 8788 Fax: +44 (0) 20 7736 8283
Printed by: Buxton Press
Reprint requests and all correspondence regarding the newspaper should be addressed to the editor at the above address.
© BIBA Medical Ltd, 2013 All rights reserved.
Write to us! If you have comments on
this issue or suggestions for upcoming editions write to
dawn@bibamedical.com
www.cardiovascularnews.com Sign up now for a free subscription
Please visit
Make sure you get your copy of Cardiovascular News
Next issue October 2013
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40